Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.53
-0.11 (-1.66%)
Nov 5, 2024, 1:24 PM EST - Market open
Recursion Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 49.64 | 44.58 | 39.84 | 10.18 | 3.96 | 2.32 |
| Revenue Growth (YoY) | -0.70% | 11.88% | 291.46% | 156.89% | 70.85% | - |
| Cost of Revenue | 322.1 | 283.81 | 203.97 | 135.27 | 63.32 | 45.81 |
| Gross Profit | -272.47 | -239.24 | -164.13 | -125.09 | -59.36 | -43.49 |
| Selling, General & Admin | 123.96 | 110.82 | 81.6 | 57.68 | 25.26 | 18.95 |
| Operating Expenses | 123.96 | 110.82 | 81.6 | 57.68 | 25.26 | 18.95 |
| Operating Income | -396.42 | -350.06 | -245.73 | -182.78 | -84.62 | -62.44 |
| Interest Expense | -0.47 | -0.1 | -0.06 | -2.95 | -1.36 | -0.64 |
| Interest & Investment Income | 16.81 | 19.12 | 6.25 | 0.07 | 0.34 | 1.74 |
| Other Non Operating Income (Expenses) | -1.27 | -1.09 | 0.05 | 0 | -0.48 | 0.01 |
| EBT Excluding Unusual Items | -381.35 | -332.13 | -239.48 | -185.65 | -86.12 | -61.32 |
| Other Unusual Items | - | - | - | -0.83 | -0.88 | -0.56 |
| Pretax Income | -380.29 | -332.13 | -239.48 | -186.48 | -87.01 | -61.88 |
| Income Tax Expense | -5.36 | -4.06 | - | - | - | - |
| Net Income | -374.93 | -328.07 | -239.48 | -186.48 | -87.01 | -61.88 |
| Net Income to Common | -374.93 | -328.07 | -239.48 | -186.48 | -87.01 | -61.88 |
| Shares Outstanding (Basic) | 228 | 208 | 176 | 125 | 22 | 22 |
| Shares Outstanding (Diluted) | 228 | 208 | 176 | 125 | 22 | 22 |
| Shares Change (YoY) | 20.41% | 18.41% | 40.04% | 475.48% | 0.98% | - |
| EPS (Basic) | -1.64 | -1.58 | -1.36 | -1.49 | -3.99 | -2.87 |
| EPS (Diluted) | -1.64 | -1.58 | -1.36 | -1.49 | -3.99 | -2.87 |
| Free Cash Flow | -342.16 | -299.74 | -120.58 | -198.41 | -51.23 | -60.95 |
| Free Cash Flow Per Share | -1.50 | -1.44 | -0.69 | -1.58 | -2.35 | -2.83 |
| Operating Margin | -798.68% | -785.33% | -616.74% | -1795.79% | -2135.66% | -2692.58% |
| Profit Margin | -755.37% | -735.99% | -601.05% | -1832.18% | -2196.01% | -2668.35% |
| Free Cash Flow Margin | -689.36% | -672.43% | -302.65% | -1949.42% | -1293.03% | -2628.37% |
| EBITDA | -364.95 | -325.66 | -233.97 | -174.37 | -80.67 | -59.95 |
| D&A For EBITDA | 31.48 | 24.4 | 11.76 | 8.41 | 3.94 | 2.49 |
| EBIT | -396.42 | -350.06 | -245.73 | -182.78 | -84.62 | -62.44 |
| Revenue as Reported | 49.64 | 44.58 | 39.84 | 10.18 | 3.96 | 2.32 |
Source: S&P Capital IQ. Standard template.
Financial Sources.